

# Constipation - Pipeline Review, H2 2019

<https://marketpublishers.com/r/CFCB48D528DEN.html>

Date: September 2019

Pages: 111

Price: US\$ 2,000.00 (Single User License)

ID: CFCB48D528DEN

## Abstracts

Constipation - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2019, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 7, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and

molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Constipation - Overview
- Constipation - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Constipation - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Constipation - Companies Involved in Therapeutics Development
- Allergan Plc
- Ardelyx Inc
- Bausch Health Companies Inc
- Braintree Laboratories Inc
- Dong-A ST Co Ltd
- Enterin Inc
- Inhibikase Therapeutics Inc
- Ironwood Pharmaceuticals Inc
- Kissei Pharmaceutical Co Ltd
- Mallinckrodt Plc
- NGM Biopharmaceuticals Inc
- RaQualia Pharma Inc
- Renexxion LLC
- Sanwa Kagaku Kenkyusho Co Ltd
- Synthetic Biologics Inc
- Yuhan Corp
- Zensun (Shanghai) Sci & Tech Co Ltd
- Constipation - Drug Profiles
- 5-BIOP - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

**Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**BLI-400 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**BLI-801 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**DA-6886 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**ENT-01 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**IKT-148009 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**lactulose 1 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**linaclotide - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**lovastatin MR - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**lubiprostone - Drug Profile**

Product Description

Mechanism Of Action

R&D Progress

mizagliflozin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plecanatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenapanor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-12852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZS-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Constipation - Dormant Projects

Constipation - Discontinued Products

Constipation - Product Development Milestones

Featured News & Press Releases

Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit

Jun 26, 2019: Knight announces filing of New Drug Submission for llsrela in Canada

Jun 20, 2019: Ironwood and Allergan's LINZESS trial meets primary endpoint

May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week

May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019

Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation

Jan 04, 2019: Ironwood and Allergan settle Linzess patent litigation with Mylan

Jan 03, 2019: Synthetic Biologics announces first two patients enrolled in phase 2b investigator-sponsored

Dec 17, 2018: Cipher Pharmaceuticals announces PLECANATIDE accepted for review by Health Canada

Nov 13, 2018: Ardelyx announces FDA acceptance of the filing of its New Drug Application for Tenapanor for the treatment of patients with IBS-C

Oct 25, 2018: Synergy Pharmaceuticals provides business update

Oct 08, 2018: Synergy pharmaceuticals presents new analyses supporting the use of TRULANCE (Plecanatide) in two patient populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Oct 08, 2018: Ironwood Pharmaceuticals presenting Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting

Oct 08, 2018: Ardelyx showcases new data from T3MPO-3 long-term safety trial of Tenapanor for IBS-C in presidential poster at ACG 2018 Annual Meeting

Oct 01, 2018: Synergy Pharmaceuticals to present new analyses of TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Constipation, H2 2019  
Number of Products under Development by Companies, H2 2019  
Number of Products under Development by Universities/Institutes, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Universities/Institutes, H2 2019  
Number of Products by Stage and Target, H2 2019  
Number of Products by Stage and Mechanism of Action, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Constipation - Pipeline by Allergan Plc, H2 2019  
Constipation - Pipeline by Ardelyx Inc, H2 2019  
Constipation - Pipeline by Bausch Health Companies Inc, H2 2019  
Constipation - Pipeline by Braintree Laboratories Inc, H2 2019  
Constipation - Pipeline by Dong-A ST Co Ltd, H2 2019  
Constipation - Pipeline by Enterin Inc, H2 2019  
Constipation - Pipeline by Inhibikase Therapeutics Inc, H2 2019  
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2019  
Constipation - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019  
Constipation - Pipeline by Mallinckrodt Plc, H2 2019  
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2019  
Constipation - Pipeline by RaQualia Pharma Inc, H2 2019  
Constipation - Pipeline by Renexxion LLC, H2 2019  
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019  
Constipation - Pipeline by Synthetic Biologics Inc, H2 2019  
Constipation - Pipeline by Yuhan Corp, H2 2019  
Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2019  
Constipation - Dormant Projects, H2 2019  
Constipation - Dormant Projects, H2 2019 (Contd..1), H2 2019  
Constipation - Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Constipation, H2 2019  
Number of Products under Development by Companies, H2 2019  
Number of Products by Top 10 Targets, H2 2019  
Number of Products by Stage and Top 10 Targets, H2 2019  
Number of Products by Top 10 Mechanism of Actions, H2 2019  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019  
Number of Products by Top 10 Routes of Administration, H2 2019  
Number of Products by Stage and Top 10 Routes of Administration, H2 2019  
Number of Products by Top 10 Molecule Types, H2 2019  
Number of Products by Stage and Top 10 Molecule Types, H2 2019

### COMPANIES MENTIONED

Allergan Plc  
Ardelyx Inc  
Bausch Health Companies Inc  
Braintree Laboratories Inc  
Dong-A ST Co Ltd  
Enterin Inc  
Inhibikase Therapeutics Inc  
Ironwood Pharmaceuticals Inc  
Kissei Pharmaceutical Co Ltd  
Mallinckrodt Plc  
NGM Biopharmaceuticals Inc  
RaQualia Pharma Inc  
Renexxion LLC  
Sanwa Kagaku Kenkyusho Co Ltd  
Synthetic Biologics Inc  
Yuhan Corp  
Zensun (Shanghai) Sci & Tech Co Ltd

## I would like to order

Product name: Constipation - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/CFCB48D528DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFCB48D528DEN.html>